INTRODUCTION
============

The incidence rate of gastric cancer (GC) is known to be high, with more than 1 million new patients affected in 2012. Although its incidence rate is declining, GC is still the second most common cancer-related cause of death worldwide.[@B1][@B2] GC is most prevalent in East Asia, including Korea and Japan by region.[@B3] The prognosis of patients with GC is highly correlated with the stage of cancer diagnosis. The 5-year survival rate of patients with early gastric cancer (EGC) is known to be over 90%.[@B4] This suggests that early detection and treatment, especially endoscopic resection, can decrease the morbidity and mortality rates of patients with GC.[@B5]

In Korea, the National Cancer Screening Program recommends a GC screening interval of 2 years for men and women aged over 40 years.[@B6] The optimal interval of endoscopic screening for the early detection of GC has been investigated in many studies. A previous study has shown that a barium meal study and subsequent endoscopic examinations at 1.5-year intervals were beneficial for the early detection of GC.[@B7] Since then, an interval of 2 or 3 years was regarded as optimal in many reports.[@B8][@B9][@B10][@B11] There were also several studies conducted on the optimal interval for high-risk groups, and one study in Korea has reported that a 1-year interval is beneficial for patients with severe intestinal metaplasia.[@B5] However, only few studies exist, and such studies report variable results.

Therefore, to clarify the optimal interval of endoscopic examination for the early detection of GC, we analyzed the clinicopathological characteristics according to the type of GC and endoscopic interval. We also confirmed the detection rate of EGC and the stage of GC according to the extent of endoscopic examination interval.

METHODS
=======

Study design
------------

We investigated patients diagnosed with and treated accordingly for GC at Kyungpook National University Chilgok Hospital between February 2014 and July 2016. The enrolled patients\' demographic and clinicopathological data were obtained prospectively using a questionnaire survey on their first visit to the outpatient clinic. Patients who underwent endoscopy within 1 year before the diagnosis of GC were excluded because of the possibility that they could have undergone endoscopy for follow-ups of uncertain diagnosis of GC or GC-related symptoms. The remaining enrolled patients were divided into two groups according to the type of GC (EGC vs. advanced gastric cancer \[AGC\]) and the interval between the time of penultimate endoscopy and diagnosis of GC (standard of 2 years and 3 years; [Fig. 1](#F1){ref-type="fig"}). EGC was defined as the presence of tumors limited to the mucosa and submucosa regardless of size or regional lymph node metastases; AGC was defined as the presence of tumors invading the submucosa.[@B9][@B12] The clinical factors included sex, age, endoscopic interval, and family history of GC. A family history of GC was defined as the presence of a first-degree relative with GC. The characteristics of the tumors, including location, size, stage, and histology, were also compared. Tumor location was confirmed using endoscopic examination. The "upper 1/3" portion included the cardia, fundus, and upper body; the "mid 1/3" portion included the mid-body; and the "lower 1/3" portion included the lower body, angle, and antrum. GC was staged in accordance with the 7th edition of the American Joint Committee on Cancer guidelines.[@B13] Tumor histology was classified according to the World Health Organization classification of GC.[@B14] Additionally, when analyzed according to the endoscopic intervals, it was classified as histologically differentiated types (including well- and moderately differentiated tubular adenocarcinoma and papillary adenocarcinoma) and undifferentiated types (including poorly differentiated tubular adenocarcinoma, poorly cohesive carcinoma including signet ring cell carcinoma, mucinous adenocarcinoma, mixed adenocarcinoma and others).[@B15][@B16]
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The treatment modalities of GC composed of endoscopic resection (endoscopic submucosal dissection or endoscopic mucosal resection), surgery, and palliative chemotherapy. We also calculated the number of patients who were transferred or lost to follow-up.

Statistical analysis
--------------------

The Student\'s t-test was used to analyze continuous variables and the χ^2^ test or Fisher\'s exact test to analyze categorical variables. To adjust for possible confounding variables, the logistic regression analysis was used. Statistical analyses and data collection were performed using the SPSS ver. 20.0 (SPSS Inc., Chicago IL, USA). A *P* value of \< 0.05 was considered statistically significant.

Ethics statement
----------------

Written informed consent was obtained from all enrolled patients. Further, the Institutional Review Board (IRB) of Kyungpook National University Chilgok Hospital approved this study (IRB No. 2012-12-152).

RESULTS
=======

Baseline characteristics according to the type of GC
----------------------------------------------------

Among a total of 974 patients, 131 were excluded owing to endoscopic interval of less than a year. Thus, 843 patients were included in the analysis. [Table 1](#T1){ref-type="table"} shows the baseline characteristics including the demographics of the enrolled patients, between the EGC and AGC groups. There were no differences in sex, age, and family history of GC between the two groups. The percentage of endoscopic interval of \< 3 years was significantly higher in the EGC group than in the AGC group (65.2% vs. 37.8%; *P* \< 0.001), which was in contrast to that of \> 5 years or no screening (25.9% vs. 57.5%; *P* \< 0.001).

###### Baseline characteristics according to the type of GC

![](jkms-33-e166-i001)

  Characteristics            EGC (n = 610)               AGC (n = 233)   *P* value    
  -------------------------- --------------------------- --------------- ------------ ----------
  Sex                                                                    0.823        
                             Male                        428 (70.2)      166 (71.2)   
                             Female                      182 (29.8)      67 (28.8)    
  Age (mean ± SD), yr        63.6 ± 11.1                 64.8 ± 12.6     0.194        
  Endoscopic interval, mon                                               \< 0.001     
                             12--24                      200 (32.8)      39 (16.7)    
                             24--36                      198 (32.5)      49 (21.0)    
                             36--60                      54 (8.9)        11 (4.7)     
                             \> 60                       49 (8.0)        37 (15.9)    
                             Never                       109 (17.9)      97 (41.6)    
  Family history of GC       115 (18.9)                  38 (16.3)       0.449        
  Location                                                                            \< 0.001
                             Upper 1/3                   77 (12.6)       62 (26.7)    
                             Mid 1/3                     55 (9.0)        39 (16.8)    
                             Lower 1/3                   477 (78.3)      131 (56.5)   
  Size, cm                                                               \< 0.001     
                             ≤ 2                         419 (68.7)      21 (9.0)     
                             2--3                        117 (19.2)      48 (20.6)    
                             3--5                        66 (10.8)       84 (36.1)    
                             \> 5                        8 (1.3)         80 (34.3)    
  Stage                                                                  \< 0.001     
                             I                           605 (99.2)      34 (14.6)    
                             II                          5 (0.8)         47 (20.2)    
                             III                         0 (0.0)         90 (38.6)    
                             IV                          0 (0.0)         62 (26.6)    
  Histology                                                              \< 0.001     
                             Tubular adenocarcinoma      460 (75.4)      130 (55.8)   
                             Papillary adenocarcinoma    7 (1.1)         3 (1.3)      
                             Mucinous adenocarcinoma     0 (0.0)         2 (0.9)      
                             Poorly cohesive carcinoma   110 (18.0)      74 (31.8)    
                             Mixed                       27 (4.4)        19 (8.2)     
                             Others                      6 (1.0)         5 (2.1)      
  Treatment                                                              \< 0.001     
                             ESD or EMR                  305 (50.0)      0 (0.0)      
                             Surgery                     250 (41.0)      139 (59.7)   
                             Palliative CTx              0 (0.0)         39 (16.7)    
                             Transfer or f/u loss        55 (9.0)        55 (23.6)    

EGC = early gastric cancer, AGC = advanced gastric cancer, SD = standard deviation, GC = gastric cancer, ESD = endoscopic submucosal dissection, EMR = endoscopic mucosal resection, CTx = chemotherapy, f/u = follow up.

Shown in [Table 1](#T1){ref-type="table"}, the tumors were mainly located in the lower 1/3rd portion in the EGC group (78.3%) and percentage of location in the upper 1/3rd portion was comparatively higher in the AGC group (EGC vs. AGC, 12.6% vs. 26.7%; *P* \< 0.001). The proportion of small-sized tumors (≤ 2 cm) was higher in the EGC group (EGC vs. AGC, 68.7% vs. 9.0%; *P* \< 0.001) and that of \> 3 cm-sized tumors was higher in the AGC group (EGC vs. AGC, 12.1% vs. 70.4%; *P* \< 0.001). The proportions of differentiated type histology and endoscopic resection were significantly higher in the EGC group than in the AGC group (all *P* \< 0.001).

Clinical characteristics according to the vigilance of endoscopic interval
--------------------------------------------------------------------------

Meanwhile, the clinicopathological characteristics according to the vigilance of endoscopic interval were analyzed. The group of patients, who underwent upper gastrointestinal endoscopic examination in \< 2 years before being diagnosed with GC showed significant differences in several variables compared with the groups of patients who underwent screening beyond 2 years and who did not undergo screening at all ([Table 2](#T2){ref-type="table"}). The tumor size tended to be small (≤ 2 cm) (\< 2 years vs. ≥ 2 years, 63.9% vs. 47.6%; *P* \< 0.001); the rate of tumor stage I was significantly higher (\< 2 years vs. ≥ 2 years, 87.4% vs. 71.2%; *P* \< 0.001); the proportion of endoscopic management increased (\< 2 years vs. ≥ 2 years, 45.8% vs. 32.4; *P* \< 0.001) ([Figs. 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}).

###### Clinical characteristics according to the vigilance of endoscopic interval (2 years)
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  Characteristics        \< 2 yr (n = 238)      ≥ 2 yr (n = 605)   *P* value
  ---------------------- ---------------------- ------------------ ------------
  Sex                                                              0.591
                         Male                   164 (68.6)         430 (71.1)
                         Female                 74 (31.1)          175 (28.9)
  Age (mean ± SD), yr    63.5 ± 11.6            64.1 ± 11.5        0.503
  Family history of GC                                             0.593
                         Yes                    40 (16.8)          113 (18.7)
                         No                     198 (83.2)         492 (81.3)
  Tumor location                                                   0.596
                         Upper 1/3              36 (15.1)          103 (17.1)
                         Mid 1/3                24 (10.1)          70 (11.6)
                         Lower 1/3              178 (74.8)         430 (71.3)
  Tumor size, cm                                                   \< 0.001
                         ≤ 2                    152 (63.9)         288 (47.6)
                         2--3                   41 (17.2)          124 (20.5)
                         3--5                   35 (14.7)          115 (19.0)
                         \> 5                   10 (4.2)           78 (12.9)
  Tumor stage                                                      \< 0.001
                         Stage I                208 (87.4)         431 (71.2)
                         Stage II               11 (4.6)           41 (6.8)
                         Stage III              13 (5.5)           77 (12.7)
                         Stage IV               6 (2.5)            56 (9.3)
  Histology                                                        0.199
                         Differentiated         146 (61.3)         340 (56.2)
                         Undifferentiated       92 (38.7)          265 (43.8)
  Treatment                                                        \< 0.001
                         ESD or EMR             109 (45.8)         196 (32.4)
                         Surgery                106 (44.5)         283 (46.8)
                         Palliative CTx         3 (1.3)            36 (6.0)
                         Transfer or f/u loss   20 (8.4)           90 (14.9)

SD = standard deviation, GC = gastric cancer, ESD = endoscopic submucosal dissection, EMR = endoscopic mucosal resection, CTx = chemotherapy, f/u = follow up.

![Tumor stage according to the vigilance of endoscopic interval.](jkms-33-e166-g002){#F2}

![Treatment modalities according to the vigilance of endoscopic interval.\
ESD = endoscopic submucosal dissection, EMR = endoscopic mucosal resection, CTx = chemotherapy, f/u = follow up.](jkms-33-e166-g003){#F3}

Additionally, the clinicopathological characteristics were analyzed on the basis of the 3-year endoscopic interval ([Table 3](#T3){ref-type="table"}). The proportions of small-sized tumor (\< 3 years vs. ≥ 3 years, 61.5% vs. 39.5%; *P* \< 0.001), tumor stage I (\< 3 years vs. ≥ 3 years, 85.0% vs. 63.3%; *P* \< 0.001), and endoscopic management (\< 3 years vs. ≥ 3 years, 43.2% vs. 26.6%; *P* \< 0.001) were significantly higher in the group with a \< 3-year interval, which was similar to that of the group with \< 2-year interval ([Figs. 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}).

###### Clinical characteristics according to the vigilance of endoscopic interval (3 years)
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  Characteristics        \< 3 yr (n = 486)      ≥ 3 yr (n = 357)   *P* value
  ---------------------- ---------------------- ------------------ ------------
  Sex                                                              0.872
                         Male                   344 (70.8)         250 (70.0)
                         Female                 142 (29.2)         107 (30.0)
  Age (mean ± SD), yr    63.9 ± 11.0            64.0 ± 12.2        0.925
  Family history of GC                                             0.678
                         Yes                    91 (18.7)          62 (17.4)
                         No                     395 (81.3)         295 (82.6)
  Tumor location                                                   0.426
                         Upper 1/3              75 (15.5)          64 (18.0)
                         Mid 1/3                51 (10.5)          43 (12.1)
                         Lower 1/3              359 (74.0)         249 (69.9)
  Tumor size, cm                                                   \< 0.001
                         ≤ 2                    299 (61.5)         141 (39.5)
                         2--3                   85 (17.5)          80 (22.4)
                         3--5                   79 (16.3)          71 (19.9)
                         \> 5                   23 (4.7)           65 (18.2)
  Tumor stage                                                      \< 0.001
                         Stage I                413 (85.0)         226 (63.3)
                         Stage II               29 (6.0)           23 (6.4)
                         Stage III              30 (6.2)           60 (16.8)
                         Stage IV               14 (2.9)           48 (13.4)
  Histology                                                        0.189
                         Differentiated         290 (59.7)         196 (54.9)
                         Undifferentiated       196 (40.3)         161 (45.1)
  Treatment                                                        \< 0.001
                         ESD or EMR             210 (43.2)         95 (26.6)
                         Surgery                222 (45.7)         167 (46.8)
                         Palliative CTx         9 (1.9)            30 (8.4)
                         Transfer or f/u loss   45 (9.3)           65 (18.2)

SD = standard deviation, GC = gastric cancer, ESD = endoscopic submucosal dissection, EMR = endoscopic mucosal resection, CTx = chemotherapy, f/u = follow up.

Detection rate of EGC and early stage of GC according to the endoscopic examination interval
--------------------------------------------------------------------------------------------

A logistic regression analysis was used to identify the detection rate of EGC according to the interval of endoscopic examination ([Table 4](#T4){ref-type="table"}). Possible confounding variables, including sex, age, family history of GC, and histology of GC at diagnosis, were adjusted for. The intervals between endoscopic examinations below 2 years and 3 years were associated with a higher proportion of detection of EGC (adjusted odds ratio \[aOR\], 2.458 and 3.022; 95% confidence interval \[CI\], 1.656--3.648 and 2.189--4.170, respectively; *P* \< 0.001). We also analyzed the detection of early stage (stage I) of GC according to the interval in the same way ([Table 5](#T5){ref-type="table"}), the possibility of early stage of GC was found to be significantly higher in below 2 and 3 years (aOR, 2.748 and 3.176; 95% CI, 1.792--4.215 and 2.270--4.444, respectively; *P* \< 0.001).

###### The odds ratios according to the endoscopic examination intervals with the type of GC (EGC vs. AGC) as the dependent variable
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  Endoscopic examination intervals, mon   aOR     95% CI         *P* value
  --------------------------------------- ------- -------------- -----------
  \< 24                                   2.458   1.656--3.648   \< 0.001
  ≥ 24                                    1                      
  \< 36                                   3.022   2.189--4.170   \< 0.001
  ≥ 36                                    1                      
  Screened                                3.144   2.225--4.442   \< 0.001
  Never been screened                     1                      

Possible confounding variables (i.e., age, sex, family history of GC and histology of GC) at diagnosis are adjusted in this analysis.

GC = gastric cancer, EGC = early gastric cancer, AGC = advanced gastric cancer, aOR = adjusted odds ratio, CI = confidence interval.

###### The ORs according to the endoscopic examination intervals with the stage of GC (stage I vs. stage II--IV) as the dependent variable
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  Endoscopic examination intervals, mon   aOR     95% CI         *P* value
  --------------------------------------- ------- -------------- -----------
  \< 24                                   2.748   1.792--4.215   \< 0.001
  ≥ 24                                    1                      
  \< 36                                   3.176   2.270--4.444   \< 0.001
  ≥ 36                                    1                      
  Screened                                2.763   1.944--3.929   \< 0.001
  Never been screened                     1                      

Possible confounding variables (i.e., age, sex, family history of GC and histology of GC) at diagnosis are adjusted in this analysis.

OR = odds ratio, GC = gastric cancer, aOR = adjusted odds ratio, CI = confidence interval.

DISCUSSION
==========

GC is still one of the most common malignancies worldwide. In 2012, nearly half of all GC cases developed in Eastern Asia.[@B17] The prognosis of GC is related to the stage at the time of diagnosis.[@B10][@B18] The 5-year survival rate of patients with EGC exceeds 90%.[@B19] The mortality rate of patients with GC in Korea has been steadily declining for the past 30 years, probably owing to the early detection and treatment of the disease after screening was introduced.[@B20] We compared EGC- and AGC-diagnosed patients using a univariate analysis. The proportions of \< 2 cm-size tumors, more differentiated histology, curative management, and \< 3-year endoscopic interval were significantly higher in the EGC group than those in the AGC group.

Several studies on the optimal interval of endoscopic examination have been conducted. The study on Chinese populations did not show a decrease in mortality with endoscopic screening every 5 years.[@B21] However, previous studies in Japan suggested that intervals of \< 1.5 or 2 years are appropriate for the early diagnosis and curative resection of GC.[@B7][@B8] In Korea, several studies showed that the effective interval to detect EGC is \< 3 years.[@B22][@B23] Other studies have suggested that biennial endoscopic screening can increase the rate of early detection of EGC and reduce the number of cases of progression to AGC.[@B10][@B24] In one cross-sectional study of these reports, the authors analyzed GC patients except the group of endoscopic resection as a treatment of GC. As a result, the 5-year GC-specific survival rates of \< 2 years interval group were significantly higher than \> 2 years interval group and the risk of AGC decreased in \< 2 years interval group.[@B24] In addition, a 1-year GC screening interval is beneficial for patients with severe intestinal metaplasia in another study.[@B5] As mentioned above, our study showed that both endoscopic intervals of \< 2 years and 3 years are appropriate for EGC detection.

Meanwhile, one study showed significant results when a family history of GC, one of the important risk factors of GC, was present. In this study, the interval of \< 3 years was effective for the group of patients who had a positive family history of GC (odds ratio \[OR\], 1.62; 95% CI, 1.10--2.37; *P* = 0.014).[@B11] Conversely, when the relationship between family history of GC and endoscopic interval was analyzed in our study, no statistically significant results were obtained. We think that further research and evaluation are needed on this subject.

In addition, a study from Korea reported that 1-year intervals of GC screening would be effective for patients with severe intestinal metaplasia.[@B5] Another study showed that a shorter endoscopic screening interval improves the optimal detection of EGC and survival.[@B23] However, we believe that a considerable portion of the GCs with \< 1-year intervals are likely to be missing cancers. One meta-analysis reported that missing cancers occur in one out of ten GCs (9.4%; 95% CI, 5.7--13.1).[@B25] Another previous meta-analysis showed 11.3% of GCs were missing cancers within 3 years before upper gastrointestinal cancer diagnosis.[@B26] Based on these findings, we excluded patients diagnosed with GC with a 1-year interval in our study.

In our study, we performed both univariate and multivariable analyses using logistic regression by dividing the patients into two groups according to the intervals of 2 years and 3 years. In the univariate analysis, the proportions of EGC (\< 2-cm size, stage I) and endoscopic resection were significantly higher in both \< 2-year and \< 3-year intervals. Further, the OR for the detection of EGC or early stage of GC in the multivariable analysis was significantly higher in both the \< 2-year and \< 3-year interval groups. The *P* value between the two ORs in both cases was less than 1. In other words, although the OR was higher in the \< 3-year interval group than in the \< 2-year interval group, it is difficult to conclude that the 3-year interval was better than the 2-year interval for EGC detection. Moreover, there was no statistically significant difference between the two groups. One study mentioned that the OR for AGC detection did not increase in the 2-year (19--30 months) (OR, 1.11) and 3-year (31--42 months) interval groups (OR, 1.21), but increased in the 4-year (43--54 months) (OR, 2.53) and 5-year (55--66 months) interval groups (OR, 2.16). Thus, such a study reported that an endoscopic examination interval of ≤ 3 years was associated with an earlier stage of GC; therefore, changing the interval of GC screening to 3 years should be considered.[@B11] Another report suggested that 3-year intervals were adequate for endoscopic treatment, but did not yield significant results in reducing the rate found in AGC.[@B10] Our findings are also consistent with such results in part. When taken together, we suggest that 3-year examination intervals are as efficient as 2-year intervals for the early detection of EGC, with a high probability of curative treatment.

Our study has several limitations. First, this study was performed in a single center; thus, we cannot conclude that the enrolled patients can represent all patients with GC. However, the total number of enrolled patients was up to 1,000, and we think that this complements such a limitation. Second, although we enrolled the patients prospectively using a questionnaire, we relied on each patient\'s memory in several parts, such as the date of penultimate endoscopy and family history of GC, which can lead to a recall bias. Third, we did not include patients diagnosed with gastric adenoma. In the hypothesis of gastric carcinogenesis called Correa\'s cascade, chronic inflammation can develop into atrophic gastritis, which in turn can progress to intestinal metaplasia, gastric adenoma and gastric adenocarcinoma.[@B27] Because gastric adenoma is a premalignant lesion, early detection and appropriate treatment will help prevent GC, particularly EGC.[@B28][@B29] In addition, a study has been conducted on the optimal endoscopic interval including gastric adenoma.[@B10] Fourth, *Helicobacter pylori* infection, one of the major risk factors for GC, was not analyzed because not all patients were tested for infection with this pathogen, and this could affect the outcome of the analysis. Fifth, this study was conducted in areas with high prevalence rate of GC; therefore, our results may not be suitable for use in areas with low prevalence rates, including Western regions. Finally, we did not analyze the survival rate. In another study, the cutoff interval to increase the risk of AGC and detect EGC was 3 years; this screening interval had a similar effect on the disease-free survival rate.[@B23] But survival rate of GC is well correlated to the tumor stage and we analyzed the stage of the GC to replace the survival rate. If we could add a direct analysis of the survival rate, it would largely support our opinion.

In conclusion, triennial endoscopic screening might be as effective as biennial screening in increasing the detection rate of EGC and rate of curative endoscopic management and in sequentially reducing the number of lesions that could progress to AGC.
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